Deciphera, GENESIS Pharma enter distribution agreement for RIPRETINIB

GENESIS Pharma and Deciphera Pharmaceuticals announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia. RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour who have received prior treatment with three or more kinase inhibitors, including imatinib.